Molecular mechanisms of diabetic cardiomyopathy

2014/01/29 by Heiko Bugger, E. Dale Abel · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cardiovascular Function and Risk Factors #Metabolism, Diabetes, and Cancer #Pancreatic function and diabetes

paper · pdf · doi:10.1007/s00125-014-3171-6

Cited by

• Pathogenetic mechanisms of septic cardiomyopathy
• Harnessing the therapeutic potential of exercise in extracellular vesicle-based therapy in metabolic disease associated cardiovascular complications
• Anti-diabetic drugs recent approaches and advancements
• Mitochondrial Mechanisms in Septic Cardiomyopathy. [europepmc]
• Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. [europepmc]
• Insulin Signaling and Heart Failure. [europepmc]
• Diabetic Cardiomyopathy: Does the Type of Diabetes Matter? [europepmc]
• Diagnostic approaches for diabetic cardiomyopathy. [europepmc]
• In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. [europepmc]
• Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. [europepmc]
• Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. [europepmc]
• Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. [europepmc]
• Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. [europepmc]
• Heart Failure in Type 2 Diabetes Mellitus. [europepmc]
• Beneficial Effects of Citrus Flavonoids on Cardiovascular and Metabolic Health. [europepmc]
• Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy. [europepmc]
• A Novel Circular RNA Mediates Pyroptosis of Diabetic Cardiomyopathy by Functioning as a Competing Endogenous RNA. [europepmc]
• Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. [europepmc]
• Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. [europepmc]
• Mitochondrial Mechanisms in Diabetic Cardiomyopathy. [europepmc]
• Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy. [europepmc]
• MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. [europepmc]
• Basic Mechanisms of Diabetic Heart Disease. [europepmc]
• Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice. [europepmc]
• FGF1 ΔHBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression. [europepmc]
• Emerging roles of exosomal miRNAs in diabetes mellitus. [europepmc]
• Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. [europepmc]
• Mitochondrial Structure and Function in Human Heart Failure. [europepmc]